Amphista Therapeutics

Company Update - October 2026

2026 has been a pivotal year for Amphista as we enter the clinic with our lead Targeted Glue™ degrader, AMX-883. Here, we highlight our latest news, select media coverage, and upcoming events.

LATEST NEWS

Amphista Therapeutics announces **first patient dosed in AMX-883** Phase 1 clinical trial for acute myeloid leukemia

- AMX-883, Amphista's first asset to enter the clinic, is a potent, selective, orally bioavailable DCAF16-mediated BRD9 degrader targeting acute myeloid leukemia (AML).
- The first-in-human **'BRAMLIE' (BR(D9) AML Interventional Evaluation)** trial will assess the safety, pharmacokinetics and preliminary efficacy of AMX-883 monotherapy in participants with AML and high-risk myelodysplastic syndrome (MDS).
- AMX-883 demonstrates karyotype-independent pro-differentiation activity pre-clinically, with the trial enrolling patients regardless of mutational status.

Read more

UPCOMING CONFERENCES

To find out more about our pipeline of Targeted Glue™ degraders, including AMX-883, **connect with our team** at upcoming events:

- **Jefferies London Life Science Week** (16-19 Nov, London)
- **American Society of Hematology (ASH)** (12-15 Dec, New Orleans)
- **J.P. Morgan Healthcare Conference** (11-14 Jan, San Francisco)

JOHN.GOODALL@AMPHISTA.COM

NEW WEBSITE

Last month, we launched our new website, reflecting our transition to a clinical stage company. With a dedicated section on AML and a strong focus on our pipeline, the new website offers deeper insight into the unmet need driving our unique target-first approach, the scientific rationale behind AMX-883, and the therapeutic potential of Targeted Glues™. **Visit here**

AMPHISTA IN THE MEDIA

Technology Networks: AML Drug Moves Into Clinical Trials Following FDA Clearance

Following FDA clearance of our investigational new drug (IND) application for AMX-883 earlier this year, Louise spoke with the writers at Technology Networks about the science behind our lead clinical program, explaining why degradation of BRD9 offers an effective therapeutic approach for treatment of acute myeloid leukemia. **Read more**

Drug Discovery Innovators & Investors: Therapies and Modalities Changing Global Drug Discovery

In September, Louise Modis, CEO, participated in Drug Discovery World's Innovators & Investors Digital Forum, exploring the shift from traditional small molecule to more targeted approaches such as AMX-883. **Watch Louise's presentation on demand here**

BBSRC: Scottish biotech spinouts pioneering new therapeutics

From pioneering research at the University of Dundee to the development of our novel Targeted Glue degraders, we're proud to see our journey recognized in a recent case study by UKRI's Biotechnology and Biological Sciences Research Council (BBSRC). The article highlights the groundbreaking work of Professor Alessio Ciulli and his team, which laid the foundations for the founding of Amphista. **Read more**

JOHN.GOODALL@AMPHISTA.COM